Sunshine Biopharma launches Everolimus in Canada

Sunshine Biopharma (SBFM) announced that its wholly owned Canadian subsidiary, Nora Pharma, has launched Everolimus in the Canadian generic prescription drugs market. Everolimus is a generic equivalent of the brand name Afinitor. Everolimus is indicated for the treatment of advanced renal cell carcinoma, breast cancer in post-menopausal women with advanced HER2-negative genotype, progressive well or moderately differentiated neuroendocrine tumors of pancreatic, gastrointestinal or lung origin, and subependymal giant cell astrocytoma associated with tuberous sclerosis complex. Nora Pharma’s Everolimus is available in strengths of 2.5 mg, 5 mg, and 10 mg and comes in blister packs of 30 tablets.